UF Innovate | The Hub News

Visitor Relationship Management Pioneer Admiral Selected to Present at the 2020 Florida Venture Capital Conference

UF Innovate | The Hub resident client Admiral, the world’s leading Visitor Relationship Management (VRM) platform, announced that it has been invited by the Florida Venture Forum (FVF) to present at the organization’s 2020 Florida Venture Capital Conference taking place in Orlando on January 30th – 31st. With a mission...

Job Interview Anxiety: How to Cope

Sweaty palms. Rapid breathing. Trouble concentrating. These are just a few of the symptoms of job interview anxiety. When speaking with a recruiter or hiring manager, the goal is to sound and appear confident, in control. Anxiety can come across as a chink in the armor. “Job interviews cause stress...

TAO Connect Adds Alcohol Prevention and Sexual Education Programs to Its Existing University Behavioral Health Services

UF startup and UF Innovate | The Hub alum TAO Connect, a digital platform designed to make behavioral health therapy more accessible and effective, announced the addition of two training programs to its online platform: the Alcohol Literacy Challenge (ALC) and the Dimensions Learning sexual education program. The evidence-based programs...

Admiral Offers Free CCPA Solution for Local Media Consortium (LMC) Members

As part of an ongoing partnership with the Local Media Consortium, UF Innovate | The Hub resident company Admiral, a pioneering innovator in AdBlock recovery and digital subscriptions, is offering free use of its CCPA management tool in 2020 for all 90 LMC publishers and their 3,300+ sites. An update...

Feathr Soars Into 2020 With $11 Million Investment Boost

UF Innovate | The Hub graduate Feathr, a Gainesville-based marketing technology provider, announced it has closed a Series B financing totaling more than $11 million led by Atlanta-based growth equity firm Fulcrum Equity Partners. The deal also included the participation from several existing investors: Freeman Digital Ventures, Florida Gulfshore Capital,...

An Edible Radio Transmitter That Monitors Medications

Eric Buffkin and Susan Baumgartner of UF Innovate | The Hub resident company etectRx®, Inc., a privately-held digital health company, speaks with James Di Virgilio, Radio Cade podcast co-host, about their patented ingestible event marker, the ID-Cap® System. The “edible radio,” powered by the chemicals in the stomach, tracks when a patient takes every dose...

Gainesville, FL, Ranked in Top 10 College Towns to Start a Business

Lafayette, IN, Columbia, MO, and East Lansing, MI, are the US’ top three college towns for starting a business, a new study from TollFreeForwarding has revealed. Gainesville is ranked as number seven, with business tax rates across all towns reviewed. Drawing on existing data, the research combined six factors tailored...

MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia

The Muscular Dystrophy Association (MDA) and UF Innovate | The Hub resident client AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich’s Ataxia (FA), announced the award of MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance AavantiBio’s phase 2 clinical trial of a gene-replacement therapy for the disease....

Oxidien Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an unmet kidney disease indication, announced that it will present at Biotech Showcase™ 2020, to be held January 13–15 at the Hilton San Francisco Union Square, in parallel with the 38th...

Oxidien Pharmaceuticals Announces Favorable Response from FDA on Proposed Development Plan

UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for secondary hyperoxaluria, announced that it has received encouraging responses from the U.S. Food and Drug Administration (FDA) regarding their proposed Phase 1/2 trial in secondary hyperoxaluria patients and other development plans...